Role of cannabinoid receptor 1 in human adipose tissue for lipolysis regulation and insulin resistance.

Image result for endocrine journal

“We recently showed that the peripheral cannabinoid receptor type 1 (CNR1) gene is upregulated by the synthetic glucocorticoid dexamethasone.

CNR1 is highly expressed in the central nervous system and has been a drug target for the treatment of obesity.

Here we explore the role of peripheral CNR1 in states of insulin resistance in human adipose tissue.

CNR1 is upregulated in states of type 2 diabetes and insulin resistance.

Furthermore, CNR1 is involved in glucocorticoid-regulated lipolysis.

Peripheral CNR1 could be an interesting drug target in type 2 diabetes and dyslipidemia.”

https://www.ncbi.nlm.nih.gov/pubmed/27858284

A Science Based Evaluation of Cannabis and Cancer

Image result for thebmj

“The irritant properties of all smoke will naturally tend to promote a pro-inflammatory immune response with the corresponding production of potentially carcinogenic free radicals. However, cannabis promotes immune deviation to an anti-inflammatory Th2 response via immune-system specific CB2 receptors. Thus, the natural pharmacological properties of marijuana’s cannabinoids, that are not present in tobacco smoke, would minimize potential irritant initiated carcinogenesis. In contrast, the pharmacological activities of tobacco smoke would tend to amplify its carcinogenic potential by inhibiting the death of genetically damaged cells. Together these observations support the epidemiological study of the Kaiser Foundation that did not find cannabis smoking to be associated with cancer incidence. Additionally, the demonstrated cancer killing activities of cannabinoids has been ignored. Cannabinoids have been shown to kill some leukemia and lymphoma, breast and prostate, pheochromocytoma, glioma and skin cancer cells in cell culture and in animals.” http://www.bmj.com/rapid-response/2011/10/29/science-based-evaluation-cannabis-and-cancer

Highest-resolution model to date of brain receptor behind marijuana’s high

“Researchers at UT Southwestern Medical Center report the most detailed 3-D structure to date of the brain receptor that binds and responds to the chemical at the root of marijuana’s high.

Their high-resolution structure of the human cannabinoid receptor 1 (CB1) and its binding site for the chemical tetrahydrocannabinol (THC) should lead to a better understanding of how marijuana affects the brain.

The research also could aid discovery of new treatments for conditions that target the receptor, said Dr. Daniel Rosenbaum, Assistant Professor of Biophysics and Biochemistry at UT Southwestern.”

https://www.sciencedaily.com/releases/2016/11/161116131935.htm

Bioactive spirans and other constituents from the leaves of Cannabis sativa f. sativa.

Image result for journal of asian natural products research

“In this paper, 17 compounds (1-17) were isolated from the leaves of Hemp (Cannabis sativa f. sativa). Among the isolates, two were determined to be new spirans: cannabispirketal (1), and α-cannabispiranol 4′-O-β-D-glucopyranose (2) by 1D and 2D NMR spectroscopy, LC-MS, and HRESIMS. The known compounds 7, 8, 10, 13, 15, and 16 were isolated from Hemp (C. sativa f. sativa) for the first time. Furthermore, compounds 8 and 13 were isolated from the nature for the first time. All isolated compounds were evaluated for cytotoxicity on different tissue-derived passage cancer cell lines through cell viability and apoptosis assay. Among these compounds, compounds 5, 9 and 16 exhibited a broad-spectrum antitumor effect via inhibiting cell proliferation and promoting apoptosis. These results obtained have provided valuable clues to the understanding of the cytotoxic profile for these isolated compounds from Hemp (C. sativa f. sativa).”

https://www.ncbi.nlm.nih.gov/pubmed/27848262

High-resolution crystal structure of the human CB1 cannabinoid receptor.

Image result for Nature journal

“The human cannabinoid G-protein-coupled receptors (GPCRs) CB1 and CB2 mediate the functional responses to the endocannabinoids anandamide and 2-arachidonyl glycerol (2-AG), as well as the widely consumed plant (phyto)cannabinoid Δ9-tetrahydrocannabinol (THC)1. The cannabinoid receptors have been the targets of intensive drug discovery efforts owing to the therapeutic potential of modulators for controlling pain2, epilepsy3, obesity4, and other maladies. Although much progress has recently been made in understanding the biophysical properties of GPCRs, investigations of the molecular mechanisms of the cannabinoids and their receptors have lacked high-resolution structural data. We used GPCR engineering and lipidic cubic phase (LCP) crystallization to determine the structure of the human CB1 receptor bound to the inhibitor taranabant at 2.6 Å resolution. The extracellular surface of CB1, including the highly conserved membrane-proximal amino-terminal (N-terminal) region, is distinct from other lipid-activated GPCRs and forms a critical part of the ligand binding pocket. Docking studies further demonstrate how this same pocket may accommodate the cannabinoid agonist THC. Our CB1 structure provides an atomic framework for studying cannabinoid receptor function, and will aid the design and optimization of cannabinoid system modulators for therapeutic ends.”

Smoking cannabis ‘may help alcoholics to quit drinking’

“Scientists have claimed that smoking weed may actually help alcoholics kick their drinking habit for good.

Despite cannabis being regarded by anti-drugs campaigners as a ‘gateway drug’ to more addictive and harder substances, experts at the University of British Columbia (UBC) in Canada think the opposite is true.

UBC researcher Zach Walsh explained: “Research suggests that people may be using cannabis as an exit drug to reduce the use of substances that are potentially more harmful, such as opioid pain medication.

“In reviewing the limited evidence on medical cannabis, it appears that patients and others who have advocated for cannabis as a tool for harm reduction and mental health have some valid points.””

https://uk.news.yahoo.com/smoking-cannabis-may-help-alcoholics-to-quit-drinking-114645222.html?soc_src=social-sh&soc_trk=fb

“Smoking Cannabis May HELP Treat Alcohol/Drug Addiction And Mental Health Disorders” http://jewishbusinessnews.com/2016/11/16/smoking-cannabis-may-help-alcoholics-to-quit-drinking/

“Smoking Marijuana Could Help Alcoholics and Opioid Addicts Treat Their Addictions” http://thescienceexplorer.com/brain-and-body/smoking-marijuana-could-help-alcoholics-and-opioid-addicts-treat-their-addictions

Non-violent drug users should face no penalty—a call from the Global Commission on Drug Policy

Image result for thebmj

“We urgently need pragmatic reform to develop effective and humane drug policies, including regulated drug markets, because prohibition has failed, write Ruth Dreifuss and Pavel Bém

The failures of prohibition—the attempt to eliminate illicit drugs for non-medical purposes through measures such as criminalisation or militarisation—and other repressive drug strategies are well documented. Over the past 50 years, they have been unable to curb either supply or demand at global or local levels. In fact, drug use, production, and trafficking, and concern about the issue among the general public, grow ever higher, while prohibition continues to exact a tragic toll on individuals and societies. Effective and humane drug policies are needed more urgently than ever.

This urgency can be felt both at the local level, where cities struggle to cope with drug use directly, and at the international level, with growing criticism of an outdated drug control system built on three United Nations conventions. Even though these conventions do not specifically insist on harsh punishment for drug use, national interpretation has favoured prohibitive approaches, with many harmful consequences.

The commission takes this a logical step further and calls for governments to regulate all illicit drugs. This would curb a massive revenue stream for organised crime, worth an estimated $320bn (£260bn; €290bn).7 It would also allow further research to inform policy and facilitate restriction of drug use—for example, setting the age of the user, maximum quantities allowed for sale or possession, and where drugs can be used. And it could help to shift perceptions from considering drugs as inherently “evil” to a more pragmatic mindset in which scientific evidence, not ideology, drives drug policy.”

http://www.bmj.com/content/355/bmj.i5921

“British Medical Journal calls for legalisation of drugs”  http://www.independent.co.uk/news/uk/crime/war-on-drugs-british-medical-journal-heroin-cannabis-cocaine-a7417171.html

 “War on drugs has failed says one of the world’s top medical journals”  http://www.mirror.co.uk/news/uk-news/war-drugs-british-medical-journal-9260434

“The war on drugs has failed and doctors should lead calls for change, says BMJ”  http://medicalxpress.com/news/2016-11-war-drugs-doctors-bmj.html

“The war on drugs has failed: doctors should lead calls for drug policy reform”  http://www.bmj.com/content/355/bmj.i6067

Medical cannabis and mental health: A guided systematic review

Image result for sciencedirect

“This review considers the potential influences of the use of cannabis for therapeutic purposes (CTP) on areas of interest to mental health professionals, with foci on adult psychopathology and assessment. We identified 31 articles relating to the use of CTP and mental health, and 29 review articles on cannabis use and mental health that did not focus on use for therapeutic purposes. Results reflect the prominence of mental health conditions among the reasons for CTP use, and the relative dearth of high-quality evidence related to CTP in this context, thereby highlighting the need for further research into the harms and benefits of medical cannabis relative to other therapeutic options. Preliminary evidence suggests that CTP may have potential for the treatment of PTSD, and as a substitute for problematic use of other substances. Extrapolation from reviews of non-therapeutic cannabis use suggests that the use of CTP may be problematic among individuals with psychotic disorders. The clinical implications of CTP use among individuals with mood disorders are unclear. With regard to assessment, evidence suggests that CTP use does not increase risk of harm to self or others. Acute cannabis intoxication and recent CTP use may result in reversible deficits with the potential to influence cognitive assessment, particularly on tests of short-term memory.

Cannabis use does not appear to increase risk of harm to self or others.”

http://www.sciencedirect.com/science/article/pii/S0272735816300939

“Marijuana could help treat drug addiction, mental health, study suggests”  https://www.sciencedaily.com/releases/2016/11/161116102847.htm

“Marijuana may help combat substance abuse, mental health disorders”  http://www.medicalnewstoday.com/articles/314159.php

“Medical cannabis may help treat mental health problems and opioid addiction”  http://www.news-medical.net/news/20161116/Medical-cannabis-may-help-treat-mental-health-problems-and-opioid-addiction.aspx

Prevalence and Patterns of Marijuana Use in Young Adults with Inflammatory Bowel Disease.

Image result for journal of pediatric gastroenterology and nutrition

“Recent studies in adults report symptom relief with marijuana use in patients with inflammatory bowel disease (IBD).

We assessed the prevalence, pattern, effects and adverse effects of marijuana use in young adults with IBD.

We conducted a prospective questionnaire survey study at a pediatric IBD clinic. All patients (18 to 21 years of age) answered anonymous questionnaires about demographics, IBD, medications and marijuana use.

Overall, 98% of patients supported legalization of marijuana and 85% were interested in using medical marijuana if it became legally available.

We found a high rate of marijuana use in our cohort of young adults with IBD. Majority of users report symptom improvement but do not inform physicians. Future well controlled studies are necessary to assess role of marijuana in IBD therapy.”

https://www.ncbi.nlm.nih.gov/pubmed/27846066

Cannabis Use as Risk or Protection for Type 2 Diabetes: A Longitudinal Study of 18 000 Swedish Men and Women.

Image result for J Diabetes Res

Whether or not cannabis use may increase or decrease the risk of type 2 diabetes is not clear. We analyzed the association between cannabis and subsequent type 2 diabetes and if a potential positive or reverse association persisted after controlling for potential confounders.

In this population-based cohort study, 17,967 Swedish men and women (aged 18-84 years), who answered an extensive questionnaire in 2002 (including questions on cannabis use), were followed up for new cases of type 2 diabetes (n = 608) by questionnaire (in 2010) and in health registers during 2003-2011. Odds ratios (ORs) with 95% CIs were estimated in a multiple logistic regression analysis. Potential confounders included age, sex, BMI, physical inactivity, smoking, alcohol use, and occupational position.

Results. The crude association showed that cannabis users had a reduced risk of type 2 diabetes OR = 0.68 (95% CIs: 0.47-0.99). However, this inverse association attenuated to OR = 0.94 (95% CIs: 0.63-1.39) after adjusting for age.

Conclusions. The present study suggests that there is no association between cannabis use and subsequent type 2 diabetes after controlling for age. To make more robust conclusions prospective studies, with longer periods of follow-up and more detailed information about cannabis use, are needed.”

https://www.ncbi.nlm.nih.gov/pubmed/27843955